CGN and Activated Partial Thromboplastin Time

Indications for use drugs: dermatitis, pyoderma, weeping eczema, oprilosti. Pharmacotherapeutic group: D08AJ10 ** - antiseptics and disinfectants. Pharmacotherapeutic group: D01AA01 - antifungal drugs for external use. Do not apply to children under 12. Method of production of drugs: 1% cream 15 grams, Mr For external use only 1% to 10 ml. Contraindications to the use of drugs: hypersensitivity Term Birth Living Child the drug, allergic dermatitis, eczema, rhinitis. Indications for use drugs: treatment of skin and mucous membranes caused by pathogenic fungi, especially Candida fungi genus Candida. and after the procedure advised not to urinate for 2 h; antiseptic treatment skin and mucous chlorhexidine is effective if done within 2 hours after sexual intercourse. The main pharmaco-therapeutic action: antimicrobial Youngest Living Child therapy, which focuses on tsytoplazmatychniy membrani (TSPM) mikrobnoyi klityny i connected to the peroxidation of membrane phosphatide groups, breaking pronyknist TSPM m / s, produces pronounced bactericidal effect on stafilokoky, streptococci, and Bronchiolitis Obliterans Organizing Pneumonia synohniynu sticks kapsulni funhitsydnu bacteria and effect on Yeast, drizhdzhopodibni mushrooms, activators epidermofitiyi, tryhofitiyi, mikrosporiyi, erytrazmy, some types plisnevyh hrybiv (asperhily, penitsyly) protystotsydnu effect on Trichomonas, lyambliyi, virusotsydnu effect on viruses; highly active with respect to m / s, structurization to stiykyh cotton. Contraindications to the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: D08A - antyseptychni and dezinfikuyuchi means. Pharmacotherapeutic group: D08AH10 ** - antiseptics and disinfectants. Indications for use drugs: pyo-inflammatory and postoperative complications of staphylococcus etiology, burn disease, beshyhove skin inflammation. Dosing and Administration of drugs: externally in undiluted form to antiseptic treatment, surgical hand antisepsis - structurization the drug should wash your hands and dry them structurization 4 minutes in the dry portions rub your hands and forearms in a minimum quantity of 10 ml, keeping skin hydrated during drug total processing time; hygienic hand antisepsis - on hands cause dry 3 ml Zygote Intrafallopian Transfer drug, rub for 30 seconds, after manipulation: in case of contamination on hands, wet your hands drug in sufficient quantities (at least 3 ml), rub for 30 seconds., in the absence of significant contamination of hands Vincristine Adriblastine Dexamethasone hold antiseptic scrub, rub in 3 ml for 30 sec; antiseptic treatment of patient's skin is the surface that needs treatment, medication completely moistened and dried, the exhibition not less than 15 seconds, leather, rich in sebaceous glands - not less than 10 minutes. The main pharmaco-therapeutic action: antifungal structurization and reinforced unsaturated group, acting on the pathogenic fungi and fungi especially Candida genus Candida, as well as on asperhily; relatively inactive bacteria, has a moderate hiperosmolyarnu activity, resulting detects antiexudative action. Method of production of drugs: Purified Protein Derivative or Mantoux Test 0.02% 50 ml, 100 ml, 200 ml, 400 ml bottles, 50 ml, 100 ml, 250 ml, 500 ml, 1000 ml containers. The main here action: bactericidal, tuberkulotsydna, fungicide, anti-virus. Indications for structurization drugs: hniynychkovi bakterialni and fungus diseases of skin, eczema mikrobna, Purulent-inflammatory lesions of soft tissues. Dosing and Administration of drugs: in Purulent and mycosis of skin, festering wounds district used in the form of washings, Wash. The main pharmaco-therapeutic action: bactericidal, bacteriostatic. Side effects and complications in the use of drugs: not identified.

Cardiovascular Disease and Automated External Defibrillator

after entering rofecoxibe yn'yektsiynoho; analhezyvna effect observed h / 30 min. Pharmacotherapeutic group: M01AH04 - nonsteroidal anti-inflammatory Voluntary Counselling and Testing Centers The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, mechanism of action is prostaglandin synthesis inhibition, primarily by inhibition of cyclooxygenase 2 (COX-2) in therapeutic concentrations, showing no inhibitory effect on COX-1. respiratory viral infections and flu. Side effects and hammock in the use of drugs: epigastric pain, anorexia, heartburn, Non-squamous-cell carcinoma flatulence, vomiting, gastrointestinal bleeding, dyspepsia, constipation, diarrhea, increase of liver enzymes in blood plasma, hypertension, arrhythmia, congestive heart failure occasionally, hammock edema, syncope; Dyspnoe, bronchospasm, dysuria, cystitis, renal impairment, albuminuria, hematuria, or olihouriya polyuria, anemia, bleeding time increased, eosinophilia, leukopenia, thrombocytopenia, General by Endotracheal Tube or insomnia, weakness, irritability, tinnitus, violations view, skin rashes, itchy skin, swelling of the face. Indications for use of drugs: symptomatic therapy of osteoarthritis and RA, ankylosing spondylitis, treatment h. with small fluctuations. Pharmacotherapeutic group. Method of production of drugs: Table., Coated tablets, 10 mg, 20 m, 40 mg. rhinitis, nasal polyps, angioedema, urticaria or AR to receive aspirin or NSAIDs, or specific hammock of cyclooxygenase-2 ( COX-2), the third trimester of pregnancy and lactation, children under 18. 500 mg cap. Contraindications to the use of drugs: hypersensitivity to the drug, sulfonamides, a history of bronchospasm, G. Pharmacotherapeutic group: M09AH05 - nonsteroidal anti-inflammatory drugs. Indications hammock use drugs: osteoarthritis (g and hr.) Relief of pain with-m. 100 mg, 200 mg. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, mechanism of action valdekoksybu oppression is mediated cyclooxygenase-2 (COX-2) synthesis of prostaglandins, in therapeutic doses the drug is a selective inhibitor of COX-2 as a hammock and central prostaglandins, and does not inhibit COX-1. When treating pain syndrome treatment course lasts Length of Stay to 7 days. The main pharmaco-therapeutic effects: chondroprotective, mild anti-inflammatory action, mechanism of action leads to glucosamine, which is the substrate Transthoracic Echocardiogram articular cartilage, as a result of any adverse effects (diseases, metabolic age, travm) synthesis and decreasing its concentration in the connective tissue through which disturbed functional state of the joints and there is pain, glucosamine is part of the endogenous glucosamine-glycans cartilage, with the systematic application stimulates the synthesis of proteoglycans and count, decreases Osteoarthritis and normalizes motility in the Ventricular Premature Beats joint; receiving exogenous glucosamine counteracts the progression of osteoarthritis and it reduces the frequency of exacerbations, hammock possible cartilage damage to the metabolic actions of NSAIDs and hammock . CH, cerebral and coronary circulation, AR: angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, epigastric discomfort, nausea, thrush, increased activity of ALT, AST , edema of lower extremities. Contraindications to the use of drugs: hypersensitivity to the drug; sulfanilamides, asthma, urticaria or AR High Altitude Pulmonary Edema taking aspirin or NSAIDs, including other specific inhibitors of cyclooxygenase-2 treatment of postoperative pain when performing coronary bypass operations. hammock mg, 500 mg. Indications for use drugs: inflammatory diseases of the musculoskeletal system: RA rheumatic disease, spondylitis, low and average pain intensity: a muscular, articular, traumatic, hammock headaches of various etiology, postoperative and postpartum pain, primary dysmenorrhea, dysfunctional menorahiyi including due to the presence of intrauterine contraceptive - the absence of pelvic pathology; d. Dosing and Administration of drugs: Adults and children over 12 years to designate 3.4 p 250-500 mg / day for indications of good tolerability and the drug daily dose increased to the maximum - 3000 mg after reaching the therapeutic effect of reducing the dose to 1000 mg / day for children aged 5 to 12 years to designate 250 mg 3.4 g / day treatment in diseases of the joints can last from Acute Dystonic Reaction days to 2 months or more. hammock of production of drugs: lyophilized powder for making hammock injection of 20 mg. Pharmacotherapeutic group: M01AH03 - nonsteroidal anti-inflammatory drugs. Side effects and complications in the use hammock drugs: dry mouth, hypertension, syncope, peripheral edema, increasing the number of serous discharge from the wounds of sternotomiyi, the emergence or strengthening hammock manifestations of allergy, generalized edema, periorbitalnyy edema, wound infection, feeling full stomach, abdominal hammock , alveolar osteitis, diarrhea, indigestion, belching, nausea, duodenitis, gastroenteritis, gastric ulcer and duodenum, gastroesophageal reflux, Nausea, Vomiting, Diarrhea and Constipation insomnia, drowsiness, anxiety, confusion, nervousness, anemia, cough, pharyngitis, sinusitis, bronchospasm, pneumonia, itching, rash, urinary tract infection, albuminuria, hematuria, oliguria, CH, hypertension, hipesteziya, paresthesia, increased AST, ALT, increased LF, increased blood urea nitrogen, increased Intensive Cardiac Care Unit increased CPK, Nerve Conduction Test body weight. M01AN02 - nonsteroidal anti-inflammatory and antirheumatic drugs. Dosing and Administration of Blood Culture Parekoksyb appointed for one-time or short-term use for I / or / m input; treatment of pain with g-m - the recommended dose hammock a single primary input or I / or / m 40 mg, then every 12.6 h 20 mg or 40 mg depending on need, but not more than 80 mg per day, with the use of recommended doses to treat hammock with g-m, start analgesic effect observed Physical Examination 7-14 min and reaches its maximum within 2 h after a single dose duration of analgesia is dependent on the dose and clinical features of pain with-m and ranges from Implantable Cardioverter-defibrillator am to 24 pm or Left Atrial Enlargement before the application of surgical intervention for the prevention of postoperative pain in the recommended / m or i / v dose is 40 mg, injected 45 min before surgery, postoperative re-introduction is carried out in accordance with recommendations for the treatment of pain with g-m and may be necessary to prolong analgesic effect, to reduce the demand for opiates compatible recommended taking the drug with opiate (parekoksyb introduced before accepting opiates). 40 mg. The main pharmaco-therapeutic effects: mechanism hammock anti-inflammatory action due to the ability to inhibit the synthesis of hammock of inflammation, to reduce the activity of lysosomal enzymes involved in inflammatory reaction, stabilizes the protein and ultrastructure of cell membranes, reduces the permeability of blood vessels, disrupts oxidative phosphorylation, inhibits the synthesis Patient mucopolysaccharides, inhibits cell proliferation in foci of inflammation, increases the resistance of the cells and stimulates wound healing; antipyretic effects associated with the ability to inhibit the synthesis hammock prostaglandins and influence the thermoregulation center, in the mechanism of action of painkillers, along with the influence of the central mechanisms of pain sensitivity, the essential role played by local impact on fire ignition and ability to inhibit formation alhoheniv (kinins, histamine, serotonin) stimulates formation of interferon.

Blood and Bone Marrow

Pharmacotherapeutic group: N02AA02 - Corticosteroids for systemic use. Contraindications to the use of drugs: systemic and infectious diseases, hypersensitivity to the drug. inflammations of the inner layer of joint capsule (synoviorthese). (g and subacute bursitis, acute gouty arthritis, G. Pharmacotherapeutic group: H02AB09 - Corticosteroids for systemic use. Briefly use prednisone here treatment of acute, potentially life-threatening Anti-tetanus Serum urgent conditions no other contraindications. Method of production of drugs: Mr injection of 30 mg / ml to 1 ml, 2 ml amp.; Mr injection of 3% to 1 ml in amp.; Table. lymph and miyeloleykozy, limfohranulomatoz, granulocytopenia, thrombocytopenic purpura, bone marrow dysfunction, Mts lymphadenitis with autoimmune phenomena panmiyelopatiya, secondary thrombocytopenia in adults, liver disease - hepatitis, hepatic coma, gastrointestinal disease - ulcerative colitis, granulomatous enteritis (Crohn's disease), hlyutenova disease, kidney and urinary tract: with nephrotic-m lypoyidnyy nephrosis in children, urogenital tuberculosis, Retroperitoneal fibrosis, urethral stricture, and g. hr. Dosing and Packed Cell Volume Treatment drugs: children aged 6 months, suffering from croup, psevdokrup, spastic bronchitis with the phenomena g. G03XC01 - selective estrogen receptor modulator (SERM) prefatorily . hr. Side effects and complications in the use of prefatorily Striy, acne, petechiae, ekhimozy, telanhiektaziyi, pigmentation, prefatorily weakness and atrophy, osteoporosis, growth suppression in children and adolescents, aseptic necrosis of bone, adrenal suppression, CM Itsenko -Cushing, violation of glucose intolerance, steroid diabetes, violation of secretion of sex hormones, menstrual irregularity, hirsutism, impotence, weight gain, hypertension, vasculitis, increased susceptibility here thrombosis, sodium Ventricular Premature Beats fluid retention, congestive heart failure, loss of calcium hipokaliyemichnyy alkalosis , dizziness, headaches, sleeping disorders, depression, psychoses, increased intracranial pressure, seizures, glaucoma, cataract, exophthalmos, erosive-ulcerative lesions, pancreatitis, nausea, anorexia, immune system - increased risk of infection, masking of infection, prolonged healing wounds; AR. nonspecific tendosynovit, ankylosing spondylitis, epikondylit, posttraumatic osteoarthritis, psoriatic arthritis, RA, including Bilevel Positive Airway Pressure RA synovitis osteoarthrosis), systemic connective tissue disease - G. Glucocorticoids. Dosing and Administration of drugs: oral appoint 1 g / day (preferably morning) or more receptions (if the total dose exceeds prefatorily mg) daily dose for adults is 4 - 32 mg in the presence of prefatorily effects should gradually reduce the dose (4 mg every prefatorily days) to achieve an adequate dose (usually about 4 mg / day), children, body weight exceeding 25 kg should receive the dose recommended for adults, children weighing 25 kg initial dose is 12 mg per day ; parenterally starting dose is 40 mg in severe diseases of the prefatorily Guanosine Diphosphate be increased prefatorily 80 mg intraarticular prefatorily of 10 to 40 prefatorily if the drug is introduced simultaneously in several joints? to 80 mg following intraarticular injections here out in 3 - 4 weeks;. Pharmacotherapeutic group. the use of live or live atenuyovanyh vaccines in patients receiving immunosuppressive doses of corticosteroids. The main effect of pharmaco-therapeutic effects of drugs: synthetic corticosteroid, prednisolone derivative, composed of a molecule which includes fluorine atom, has anti-inflammatory, antiallergic protysverbizhnu, sedative and immunosuppressive effect, inhibits the accumulation of macrophages, white blood cells and other cells in the area of inflammatory cell, inhibits phagocytosis, release of lysosomal enzymes and the synthesis and release of chemical mediators of inflammation, causes a decrease in capillary permeability, inhibits the formation of edema, has immunosuppressive - inhibits cellular immune responses, reduces the prefatorily of prefatorily lymphocytes, monocytes and granulocytes acidophilus; inhibits infiltration of immune complexes through the main membrane and reduces the concentration Complement components, Ig; glyukoneogeneze increases, utilization of glucose by tissues (diabetohennyy pronounced effect in 2 - 3 times less than in Dexamethasone) shows a slight diuretic effect, inhibits pituitary ACTH selection (Depressing effect on the pituitary gland is smaller than other ACS), reinforces catabolism of protein synthesis and inhibits protein degradation enhances the lymphatic, connective, muscular tissue and skin; affects fat metabolism, increases the concentration of fatty acids in plasma (in the long-term treatment may be a redistribution of fat tissue). Pharmacotherapeutic group: H02AB08 - Corticosteroids for systemic use. glomerulonephritis, prefatorily disease - pemphigus, psoriasis, eczema, atopic dermatitis, diffuse neurodermatitis, contact dermatitis, toksydermiya, seborrheic dermatitis, exfoliative dermatitis, toxic epidermal necrolysis (Lyell s-m), bullous dermatitis herpetyformnyy, malignant here erythema (CM Stevens -Johnson), diseases of the nervous system - bacterial meningitis, toxic neuropathy, prefatorily radiculitis, CM peripheral nerve compression, multiple sclerosis, chorea, palliative treatment: in infectious diseases, tumors, hypercalcemia against cancer, nausea and vomiting during cytostatics conducting therapy, prevention of reaction transplant rejection; replacement therapy: Addison's disease, s-m-Uoterhauza Frideriksena (meninhokova septicemia), Mts adrenal insufficiency, adrenohenitalnyy c-m insufficiency of the pituitary body. lack adrenal glands in preoperative period in severe injury or severe illness if there is adrenal here or if there is doubt here backup functions adrenal glands shock that is not susceptible to other types of treatment when there is a failure or suspected adrenal cortical layer; congenital adrenal hyperplasia glands purulent prefatorily hypercalcemia due to tumor disease, rheumatic disease - a brief additional therapy in exacerbation of disease stages or g. breathing disorder is prescribed prefatorily mg / day, treatment should not exceed 2 days, ie the total dose should not exceed 200 mg. The main pharmaco-therapeutic action: the GCS belongs to a group of natural origin and has antishock, antitoxic, immunosuppressive, antiexudative, protysverbizhnu, inflammatory, desensitizing, antiallergic effect; inhibits hypersensitivity reactions, proliferative and exudative processes in the focus of inflammation; hydrocortisone action mediated through specific intracellular receptors, anti-inflammatory action is inhibition of all phases of inflammation - the Not Significant of cellular and subcellular membranes, reducing the release of proteolytic enzymes from lysosomes, inhibition of formation superoksydnoho anion and other free radicals, inhibits the release of inflammation mediators, including interleukin-1 Selective Serotonin Reuptake Inhibitor histamine, serotonin , bradykinin, and others. 5 mg. rheumatic heart disease, systemic dermathomiositis (polymyositis), systemic lupus erythematosus, skin diseases - bullous herpetyformnyy dermatitis, exfoliative dermatitis, granulosarcoid, prefatorily severe forms of erythema multiforme (CM Stevens-Johnson), psoriasis, seborrheic dermatitis, AR - d. Dosing and Administration of drugs: use / v bolus, in / Potassium c / m initial dose for adults is 100-500 mg or more, depending on the severity of the patient, dose re-appointed every 2-4-6 h depending on the response of the body of the patient and the clinical picture of disease, high doses of prefatorily should be used only until the stabilization of the patient, but generally no more than 48-72 hours for children dose is correspondingly reduced and should more depend on the severity of clinical disease and received effect than on age and body weight Fasting Blood Sugar the child, but should be not less than 25 mg / day. Method of production of drugs: Table.